Price$28.57-0.93 (-3.15%)
2026-03-042026-06-05
News · 26 weeks75-50%
2025-12-142026-06-07
Mix3690d
- Insider18(50%)
- SEC Filings8(22%)
- Other5(14%)
- Earnings4(11%)
- Analyst1(3%)
Latest news
25 items- INSIDERPresident & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85, sold $6,054,000 worth of shares (200,000 units at $30.27) and covered exercise/tax liability with 34,483 shares, decreasing direct ownership by 2% to 1,613,063 units (SEC Form 4) (withholding obligation)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERCFO Pulik Richard covered exercise/tax liability with 18,962 shares, decreasing direct ownership by 6% to 278,549 units (SEC Form 4) to satisfy withholding tax4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECSEC Form S-8 filed by Roivant Sciences Ltd.S-8 - Roivant Sciences Ltd. (0001635088) (Filer)
- SECSEC Form 10-K filed by Roivant Sciences Ltd.10-K - Roivant Sciences Ltd. (0001635088) (Filer)
- SECRoivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- PRRoivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business UpdateIMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026 Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline Phase 3 data for brepocitinib in no
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
- PRRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the confere
- PRImmunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant's website after the conference call. About Immunovant Immunova
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
- INSIDERSEC Form 4 filed by Venker Eric4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Pulik Richard4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Humes Jennifer4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Oren Ilan4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Epperly Melissa B,4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Momtazee James C4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Gline Matthew4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECSEC Form 144 filed by Roivant Sciences Ltd.144 - Roivant Sciences Ltd. (0001635088) (Subject)
- INSIDERSEC Form 4 filed by Humes Jennifer4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Torti Frank4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECRoivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- PRPriovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its
- PRRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its
- INSIDERSEC Form 4 filed by Gline Matthew4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Sukhatme Mayukh4 - Roivant Sciences Ltd. (0001635088) (Issuer)
ROIV FAQ
6 questionsWhat does Roivant Sciences Ltd. do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.Where does ROIV stock trade?
Roivant Sciences Ltd. (ROIV) is listed on NASDAQ.What sector and industry is ROIV in?
Roivant Sciences Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ROIV?
Roivant Sciences Ltd. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Outperform with a $3500.00 price target on 2026-03-20. Recent price targets range from $1050.00 to $3500.00.What companies are similar to ROIV?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ROIV side-by-side with any of them on Quantisnow.How can I track ROIV on Quantisnow?
Quantisnow aggregates Roivant Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ROIV to receive live email and push alerts on every new disclosure.